In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tom Gallen

Managing Editor – Europe

Having joined OTC bulletin as a business reporter in 2013, Tom is currently the managing editor and has an intimate knowledge of the global consumer healthcare market, particularly commercial and regulatory issues. He specializes in analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios.
Set Alert for Articles By Tom Gallen

Latest From Tom Gallen

Germany's Neuraxpharm Underlines OTC Ambitions With Easypharm Acquisition

Austria's Easypharm has been snapped up by Neuraxpharm, which is looking to take a larger slice of Europe's consumer healthcare market.
Austria Germany

Dermocosmetics Push Yields Results For Switzerland's Galenica

Launching skin-care products that blend "natural medicinal plants from the Swiss pharmacopoeia with the best Swiss skin science" helped to drive up Galenica's OTC sales in 2019 at a double-digit rate.
Switzerland Health

Polish Industry Fighting Against Advertising Tax On Supplements

Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.
Poland Wellness

French OTC Industry Frustrated By Regulatory Clampdown in 2019

Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.
France OTC Drugs

No More ‘Major’ Deals For GSK Consumer Before IPO – CEO Walmsley

GSK's CEO Emma Walmsley has effectively ruled out further big deals at its Consumer Healthcare unit before the business is separated from its parent through an IPO. 
Business Strategies OTC Drugs

HRA Pharma Taking On China With JV Partner

HRA is putting feet on the ground in China as it looks to establish itself in the world second-largest consumer health market. 
China Health
See All
UsernamePublicRestriction

Register